Amova Asset Management Americas Inc. Has $101.13 Million Holdings in Natera, Inc. $NTRA

Amova Asset Management Americas Inc. decreased its holdings in Natera, Inc. (NASDAQ:NTRA) by 12.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 628,594 shares of the medical research company’s stock after selling 90,468 shares during the quarter. Natera accounts for approximately 1.0% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 28th biggest holding. Amova Asset Management Americas Inc. owned 0.46% of Natera worth $101,128,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC lifted its holdings in shares of Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 110 shares in the last quarter. Quent Capital LLC purchased a new stake in Natera in the 3rd quarter valued at $46,000. Hilltop National Bank lifted its stake in Natera by 59.8% during the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock valued at $50,000 after acquiring an additional 116 shares in the last quarter. N.E.W. Advisory Services LLC boosted its holdings in Natera by 256.8% during the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after acquiring an additional 226 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in Natera by 23.1% during the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock worth $69,000 after acquiring an additional 81 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Signatera is being highlighted as a primary growth driver for Natera’s oncology business, supporting revenue momentum and investor optimism about recurring MRD testing demand. Signatera Oncology Test Drives Natera’s (NTRA) Growth
• Positive Sentiment: Management presented at TD Cowen’s healthcare conference; the transcript emphasizes commercial progress across oncology (Signatera), reproductive health and transplant products, reinforcing the narrative behind recent revenue beats. Natera Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Positive Sentiment: Coverage noting why the stock traded up ties the move to the company’s recent operational beats and growth commentary, which can amplify buying interest on upside news. Natera (NTRA) Stock Trades Up, Here Is Why
• Neutral Sentiment: Morgan Stanley trimmed its price target from $265 to $250 but kept an Overweight rating — a modestly negative signal on price scope but still reflects continued analyst confidence. Morgan Stanley Lowers Price Target
• Neutral Sentiment: MarketBeat/analyst notes show a consensus “Moderate Buy” and a cluster of raised targets from other firms, indicating mixed but generally constructive analyst sentiment that could limit downside. NTRA MarketBeat Summary
• Negative Sentiment: Insider selling: CEO Steven Chapman and longtime insider Solomon Moshkevich sold shares in early March (transactions near $200/sh), which can weigh on sentiment even if the trades appear to be routine liquidity. Natera Insider Sells $599,550.00 in Stock

Natera Price Performance

NASDAQ:NTRA opened at $203.03 on Thursday. The company has a market capitalization of $28.78 billion, a P/E ratio of -132.70 and a beta of 1.65. The business has a fifty day simple moving average of $224.59 and a two-hundred day simple moving average of $204.76. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same quarter in the prior year, the company earned ($0.41) EPS. As a group, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $199.85, for a total value of $599,550.00. Following the completion of the transaction, the insider directly owned 150,023 shares in the company, valued at approximately $29,982,096.55. The trade was a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 6,939 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $227.83, for a total value of $1,580,912.37. Following the sale, the chief financial officer owned 52,120 shares in the company, valued at approximately $11,874,499.60. The trade was a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 367,669 shares of company stock worth $85,584,453. 5.63% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on NTRA shares. Wells Fargo & Company raised their price target on shares of Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Guggenheim increased their price objective on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Evercore upped their target price on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Citigroup began coverage on Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.